Published in final edited form as:

Pediatrics. 2009 January ; 123(1): 378–390. doi:10.1542/peds.2008-0317.

Advances in the Treatment of Fragile X Syndrome

Randi J. Hagerman, MD^{a,b}, Elizabeth Berry-Kravis, MD, PhD^{c,d,e}, Walter E. Kaufmann, MD, PhD^f, Michele Y. Ono, MS^{a,b}, Nicole Tartaglia, MD^g, Ave Lachiewicz, MD^{h,i}, Rebecca Kronk, PhD, CRNP^{j,k}, Carol Delahunty, MD^l, David Hessler, PhD^{a,m}, Jeannie Visootsak, MD^{n,o}, Jonathan Picker, MD^{p,q}, Louise Gane, MS^{a,b}, and Michael Tranfaglia, MD^r

^aMIND. Institute and Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento, California ^bDepartment of Pediatrics, University of California, Davis, School of Medicine, Sacramento, California ^cDepartment of Pediatrics, Rush University Medical Center, Chicago, Illinois ^dDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois ^eDepartment of Biochemistry, Rush University Medical Center, Chicago, Illinois ^fCenter for Genetic Disorders of Cognition and Behavior, Kennedy-Krieger Institute, John Hopkins University School of Medicine, Baltimore, Maryland ^gDepartment of Pediatrics, University of Colorado at Denver Health Sciences Center, Denver, Colorado ^hDepartment of Pediatrics, Duke University Medical Center, Durham, North Carolina ⁱDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina ^jDepartment of Psychology in Education, University of Pittsburgh, Pittsburgh, Pennsylvania ^kSchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania ^lNeuro Developmental Center, Akron Children's Hospital, Akron, Ohio ^mDepartment of Psychiatry and Behavioral Sciences, University of California, Davis, School of Medicine, Sacramento, California ⁿDepartment of Human Genetics, Atlanta, Georgia ^oDepartment of Pediatrics, Emory University, Atlanta, Georgia ^pDepartment of Genetics, Children's Hospital Boston, Boston, Massachusetts ^qDepartment of Child and Adolescent Psychiatry, Children's Hospital Boston, Boston, Massachusetts ^rFRAXA Research Foundation, Newburyport, Massachusetts

Abstract

The *FMR1* mutations can cause a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socioemotional problems, in individuals with the full mutation form (fragile X syndrome) and distinct difficulties, including primary ovarian insufficiency, neuropathy and the fragile X-associated tremor/ataxia syndrome, in some older premutation carriers. Therefore, multigenerational family involvement is commonly encountered when a proband is identified with a *FMR1* mutation. Studies of metabotropic glutamate receptor 5 pathway antagonists in animal models of fragile X syndrome have demonstrated benefits in reducing seizures, improving behavior, and enhancing cognition. Trials of metabotropic glutamate receptor 5 antagonists are beginning with individuals with fragile X syndrome. Targeted treatments, medical and behavioral interventions, genetic counseling, and family supports are reviewed here.

Copyright © 2009 by the American Academy of Pediatrics

Address correspondence to Randi J. Hagerman, MD, MIND. Institute, UC Davis Health System, 2825 50th St, Sacramento, CA 95817. randi.hagerman@ucdmc.ucdavis.edu.

Financial Disclosure: Drs Hagerman, Berry-Kravis, and Hessler receive grant support from Neuropharm to conduct a study of fenobam with individuals with FXS. The other authors have indicated they have no financial relationships relevant to this article to disclose.

Keywords

fragile X syndrome; autism; behavioral interventions; fragile X mental retardation protein; targeted treatments; fenobam

FRAGILE X SYNDROME (FXS) is associated with an array of intellectual and emotional disabilities, ranging from mental retardation (hereafter referred to as intellectual disability) to learning problems, autism, and anxiety. The cause of FXS is decreased or absent levels of fragile X mental retardation protein (FMRP). Decreased levels of FMRP typically are caused by the full mutation (>200 CGG repeats), which usually is methylated, in the proximal regulatory region of *FMR1* (fragile X mental retardation 1 gene).¹⁻³ FXS occasionally occurs because of a point mutation or deletion in *FMR1*^{4,5} or even a smaller expansion in the CGG repeat, which leads to lower levels of FMRP and intellectual disability.⁶ Intellectual disability linked to FXS occurs in ~1 per 3600 individuals in the general population,^{7,8} whereas milder cognitive and behavioral problems (eg, math and language deficits, social phobia, and attention-deficit/hyperactivity disorder [ADHD]) associated with FXS may be more common. A more-frequent (1 of 130–250 female individuals and 1 of 250–800 male individuals) but smaller expansion (55–200 CGG repeats) of *FMR1* is termed a premutation.⁹⁻¹² In contrast to the full mutation, the premutation usually does not cause decreased FMRP levels but leads to enhanced production of *FMR1* mRNA (2–8 times normal levels)^{13,14} (Fig 1). The enhanced mRNA production can lead to clinical features in premutation carriers that do not occur in full mutation carriers, including primary ovarian insufficiency and the fragile X-associated tremor/ataxia syndrome (FXTAS).

In general terms, the severity of the FXS physical phenotype and intellectual impairment is correlated with the magnitude of the FMRP deficit.^{1,2,15} Male individuals with incomplete methylation of a full mutation (methylation mosaicism) or a mixture of the premutation and full mutation alleles (allele size mosaicism) and female individuals with a favorable activation ratio (proportion of cells that have the normal X chromosome as the active X chromosome) generally have the highest levels of FMRP and the highest IQs.^{1,2,15,16} Male individuals with a completely methylated full mutation commonly display mild to moderate intellectual disability. Female individuals with the full mutation typically present with learning disabilities, although ~25% have intellectual disability.¹⁷ Most individuals with the premutation have a normal IQ, although mild cognitive and behavioral problems (eg, executive dysfunction, social deficits, anxiety, and obsessive-compulsive behavior) have been reported, particularly for male individuals.¹⁸⁻²⁴ Children with the premutation occasionally present with physical or behavioral features of FXS, including large ears, hand flapping, poor eye contact, and social deficits consistent with autism spectrum disorder (ASD); this presumably is related to mild deficits in FMRP.^{6,18,21,23} The premutation also can cause clinical involvement that is related to RNA toxicity resulting from elevated mRNA levels, which is not seen with the full mutation.^{14,22,25,26} Approximately 20% of female individuals with the premutation have primary ovarian insufficiency,²⁷ and ~40% of aging male individuals and 4% to 8% of aging female individuals with the premutation develop FXTAS.^{28,29} FXTAS includes intention tremor, ataxia, neuropathy, autonomic dysfunction, brain atrophy, and cognitive decline.³⁰⁻³³ Recent research also demonstrated an increased frequency of autoimmune disorders, including hypothyroidism and fibromyalgia, in female individuals with the premutation, compared with control female subjects.²⁹ Both premutation involvement and full mutation involvement make FXS a family affair, with an array of disorders seen throughout multiple generations (Fig 2).³⁴ Once a proband is diagnosed, the clinician should address issues regarding treatment, referral, and genetic counseling for multiple family members.^{29,35-37}

This review addresses treatment issues related to behavioral problems for individuals affected by FXS. Information on treatment regarding medical complications of FXS,³⁷⁻⁴³ primary ovarian insufficiency,⁴⁴ and FXTAS³⁶ can be found elsewhere. The few controlled and open trials of medication use in FXS are reviewed. Most FXS medication studies are surveys of clinical populations, as described below, and additional controlled studies are needed. The input of clinicians from the Fragile X Research and Clinical Consortium, an international network of FXS clinics established by the National Fragile X Foundation in 2006, was used to complete this report.

BEHAVIORAL FEATURES AND TREATMENT

Behavioral Phenotype

The behavioral phenotype of FXS involves poor eye contact, excessive shyness, anxiety, hand flapping, hand biting, aggression, tactile defensiveness, attention deficits, hyperactivity, impulsivity, hyperarousal to sensory stimuli, and ASD.^{16,41,45-54} In female individuals with FXS, the behavioral phenotype is characterized by relatively milder cognitive and behavioral problems than those observed for male individuals, including shyness, social anxiety, features of ADHD combined with language and other learning deficits (eg, math disability), and mood lability.⁵⁵⁻⁵⁷ Female individuals typically are less affected than male individuals because their normal X chromosome yields some FMRP (related to the X activation ratio). Only ~25% of female individuals with the full mutation have an IQ of <70, although the majority present with the aforementioned learning and/or behavioral problems.^{17,58}

Similar to avoidant and anxious behavior, most boys with FXS display autistic behavior,^{59, 60} and ~30% meet formal Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for autistic disorder.^{45,60-64} Autism is a major concern in FXS because it is associated with more-severe impairment of social interactions, in addition to lower cognitive ability, academic achievement, adaptive behavior, and language ability than seen in individuals with FXS without autism.⁶³⁻⁶⁸

Treatment of ADHD

Relative to individuals with other genetic conditions or individuals with nonspecific intellectual disability, the prevalence of ADHD symptoms in children with FXS is higher.^{49,69-71} In addition to behavioral intervention and individualized therapies, stimulants were shown to improve symptoms of ADHD in FXS in 1 controlled trial,⁷² in surveys of medication use in FXS,^{73,74} and in 1 psychophysiologic study of FXS.⁷⁵ Those studies indicated that stimulants, at usual doses, were the most frequently used class of medication for boys with FXS⁷²⁻⁷⁴ and they were thought to help in ~70% of cases, on the basis of clinical evaluations.

Treatment of ADHD symptoms in younger children (< 5 years of age) is particularly challenging. Stimulants may induce irritability and other behavioral problems in children <5 years of age; therefore, nonstimulant medications may be helpful.³⁷ α -Adrenergic receptor agonists, including clonidine and guanfacine, seem to be the best option for younger children or neurologically more affected children who do not fare well with stimulants. In a survey of clonidine use among 35 children with FXS, 63% of parents thought that clonidine was very helpful for their child, whereas 20% found clonidine to be a little helpful, 11% thought that behavior was worse, and 6% thought that there was no effect.⁷⁶ The average dose was 0.15 mg/day. Clonidine was prescribed most often to treat hyperactivity, overstimulation, and attention/concentration problems. Clonidine was used as monotherapy for preschool-aged children and was used in conjunction with another medication for the majority of older children.⁷⁶ The results of that study were similar to the 70% response rate for α -adrenergic receptor agonists from clinic-based evaluations of 27 treated patients.⁷⁴ Clonidine can be beneficial for

children with ADHD who have sleep disturbances, and sleep problems often are present among children with FXS.^{37,77}

Guanfacine can improve ADHD symptoms, including hyperactivity and frustration intolerance, as well as hyperarousal in children without FXS.⁷⁸⁻⁸⁰ Our clinical experience has demonstrated guanfacine to be helpful in FXS because it generally is less sedating than clonidine and it has a longer half-life; therefore, twice-daily dosing usually is sufficient. A dose of 0.1 mg of clonidine is equivalent to a dose of 1 mg of guanfacine, and abrupt withdrawal should be avoided for both drugs.⁸¹

Two controlled trials of the nonstimulant L-acetyl-carnitine, at dosages of 20 to 50 mg/kg per day, for treatment of ADHD in boys with FXS have been reported.^{82,83} Both studies demonstrated efficacy of L-acetyl-carnitine in the treatment of ADHD symptoms, but the effects were more remarkable in the parent reports than in the teacher reports. These trials of L-acetyl-carnitine were conducted in European countries where the use of stimulant medications either is not allowed or is discouraged, and L-acetyl-carnitine seems to be a reasonable alternative.

Treatment of Anxiety

Selective serotonin reuptake inhibitors (SSRIs) at typical doses were helpful >50% of the time in relieving anxiety and related problems, in surveys of patients with FXS.^{74,84} Selective mutism is a form of anxiety in some female individuals with FXS; it is rare among male individuals with FXS. Fluoxetine can be beneficial for this problem, as reported for 1 family with FXS.⁸⁵ As reported for idiopathic autism,⁸⁶⁻⁹³ SSRIs can be helpful for individuals with FXS, on the basis of survey reports and clinical series.^{73,74,84}

Genotypic differences in gene polymorphisms regulating serotonin seem to modify the expression of aggressive and stereotypic behaviors in male individuals with FXS and may be related to SSRI treatment responses.⁹⁴ Specifically, male individuals with FXS who were homozygous for the high-transcribing, long serotonin transporter-linked polymorphic region genotype had the most aggressive and destructive behavior and individuals who were homozygous for the short genotype had the least aggressive behavior. There was no effect of the monoamine oxidase A polymorphism on behavior; however, individuals with the high-activity, 4-repeat genotype were more likely to be taking SSRI or serotonin/norepinephrine reuptake inhibitor medication.

Activation with SSRIs occurred for ~20% of individuals with FXS who were surveyed.⁸⁴ Activation may be manifested as restlessness, mood changes, and disinhibited behaviors, including aggression. Fluoxetine may be the most activating and is not the SSRI of choice for very hyperactive patients with FXS, but it may be useful for individuals with social anxiety, autism, or selective mutism.⁷⁴ SSRIs may lead to suicidal ideation among depressed patients (although this has never been reported for FXS), and careful monitoring of patients for mood changes is justified. To date, no completed suicides have been attributed to SSRI use among youths with or without FXS, according to the Food and Drug Administration.⁹³

Treatment of Aggression and Mood Instability

Antipsychotic drugs generally are helpful in clinical settings to target irritability, aggression, mood instability, and perseverative behaviors in both male individuals and female individuals with FXS. In a study of a large FXS clinic population, ~80% of individuals with FXS responded to ≥1 antipsychotic drug, without adverse effects requiring withdrawal.⁷⁴ Risperidone (Risperdal [Janssen Pharmaceutica Products, LP, Titusville, NJ]) was the most frequently used antipsychotic drug in the past and was effective clinically, with high response rates for aggressive behavior in older male individuals with FXS and other irritable, aberrant, and

undesired behaviors in young boys with FXS and autistic traits.⁷⁴ These results are consistent with the finding that risperidone was safe and effective for aggressive and aberrant behaviors in a double-blind, placebo-controlled trial with individuals with autism who did not have FXS.⁹⁵ The typical risperidone dose range for children with FXS is 1 to 2.5 mg/day.

Aripiprazole (Abilify [Bristol-Myers Squibb Co, Princeton, NJ]) was the second most frequently used atypical antipsychotic agent in a FXS clinic survey,⁹⁶ with the highest overall response rate (~71%) for an individual-antipsychotic and the lowest concern about weight gain.⁹⁷ Because of its unique pharmacologic profile, aripiprazole targets multiple behavior difficulties in FXS, including distractibility, anxiety, mood instability, aggression, and aberrant social behaviors. Typically, low doses of aripiprazole (2.5–5.0 mg for adolescents and even lower doses for younger children, eg, ≤1 mg at bedtime) work best for patients with FXS, because agitation is a common finding at higher doses. If agitation occurs, then the dose should be decreased. Most of our information on medication use in FXS is from medication surveys and clinical experience, and there is a tremendous need for controlled trials to confirm this information and to document efficacy and safety, particularly for long-term use.

Treatment of the Prader-Willi Phenotype

A subgroup of male individuals with FXS have hyperphagia and obesity that develop in early to middle childhood, with a physical phenotype similar to that of Prader-Willi syndrome but with negative results of molecular testing for 15q11 abnormalities. This was first described as the Prader-Willi phenotype (PWP) of FXS in 1987⁹⁸; since then, ~25 additional cases have been described.^{99–101} Symptoms of autism are more common with the PWP, with a recent study showing 54% of patients with autism, compared with ~30% of patients with FXS without the PWP.¹⁰¹

Recent molecular research showed that expression of cytoplasmic *FMRI*-interacting protein 1 (CYFIP1) was decreased in individuals with the PWP, compared with both control subjects without FXS and patients with FXS without the PWP.¹⁰¹ This finding is especially interesting because the *CYFIP1* gene is located in the Prader-Willi critical region of 15q,¹⁰² and CYFIP1 interacts with FMRP in neurons during synaptic development and plasticity.¹⁰³ Recently, a study of lymphoid cells from boys with either FXS and autism or autism associated with chromosome 15 duplication demonstrated that both groups had abnormal expression of *GP155* (G protein-coupled receptor 155), a gene regulated by CYFIP1.¹⁰⁴ This finding of one of the first abnormalities seen in >1 autistic disorder may explain the high frequency of autism in PWP.

Treatment considerations for children with the PWP include early implementation of strategies developed for Prader-Willi syndrome, to address the weight gain associated with the onset of hyperphagia. These strategies include consultation and follow-up monitoring with a dietician, regular physical exercise, environmental modifications (eg, locking the kitchen or cupboards), and programs such as the Food Security and Red, Yellow, Green dietary programs developed for Prader-Willi syndrome.^{105–107} Aggressive screening and treatment of complications of early obesity, such as hypertension, type 2 diabetes mellitus, dyslipidemias, and obstructive sleep apnea, should be performed. In addition, psychopharmacologic and anticonvulsant medications that are less likely to precipitate weight gain should be used; for example, aripiprazole should be used instead of risperidone if an atypical antipsychotic agent is used for treatment of aggression or mood instability.¹⁰⁵

Seizures and Treatment

Individuals with FXS have increased risk for seizures, with rates of 13% to 18% for boys and ~5% for girls.^{108–112} In general, the risk of epilepsy onset seems to be highest in childhood;

one study suggested that the peak incidence was between the ages of 6 months and 4 years, with a mean age of onset of 2 years.¹¹¹ In addition, many individuals have abnormal electroencephalographic findings without overt epileptic seizures. More than 50% of electroencephalographic abnormalities seem to resemble those observed in childhood epilepsy (benign focal epilepsy of childhood and benign Rolandic epilepsy), with centrotemporal spikes.^{111,113,114} However, a wide range of seizure types have been reported in FXS. The most common seizure type is complex partial seizures,^{110,111} although simple partial febrile convulsions and generalized tonic-clonic seizures may occur. Status epilepticus has been reported but is relatively rare in FXS.¹¹⁰

The majority of individuals with FXS experience resolution of their epilepsy during childhood. Although the type of seizures (partial or generalized) does not seem to predict seizure remission, the centrotemporal spike pattern on electroencephalograms seems to be an excellent prognostic factor for remission of epilepsy, as in benign focal epilepsy of childhood.¹¹¹ Poor seizure control and a focal, frontal, rhythmic, slowing pattern on electroencephalograms may be risk factors for the persistence of epilepsy into adulthood. Recurrent seizures may be an indicator of increased risk for autism in FXS, because individuals with FXS and autism have seizure rates 3 times those of individuals with FXS alone.¹¹⁵

Seizures in FXS generally are easily controlled with a single anticonvulsant. Treatment involves the use of the range of anticonvulsant medications; however, because FXS is associated with hypotonia, loose connective tissue, and cognitive and behavioral problems, these issues should be taken into account when the choice of medication is being considered. Adverse effects that exacerbate hypotonia, clumsiness, cognitive dulling, and daytime sedation are particularly undesirable. Historically, most individuals with FXS have experienced good control with carbamazepine or valproic acid, with fairly limited adverse effects. More recently, lamotrigine (Lamictal [GlaxoSmithKline, Research Triangle Park, NC]), oxcarbazepine (Trileptal [Novartis Pharmaceuticals Corporation, Suffern, NY]), zonisamide (Zonegran [Elan Biopharmaceuticals, Inc, San Diego, CA]), and levetiracetam (Keppra [UCB Pharma, Inc, Smyrna, GA]) have proven to be effective potential additions to the anticonvulsant regimen for patients with seizures that are difficult to control, with the advantage of minimal cognitive adverse effects. Phenytoin generally is avoided, if possible, for children with FXS because of the adverse effects of gum hypertrophy and tissue overgrowth, coupled with the difficulty of managing dental problems in these oversensitive children. Phenobarbital and gabapentin also should be avoided, because they exacerbate behavioral problems, including hyperactivity, in individuals with FXS. Levetiracetam occasionally worsens irritability and aggressive behavior, although some individuals with FXS have positive behavioral and anticonvulsant responses, in our clinical experience. Because a wide range of anticonvulsants with good safety profiles are now available, individuals who are not attaining control or who are experiencing significant adverse effects should be switched to reasonable alternative preparations.

In the future, direct effects on the biological deficits resulting from deficient FMRP may offer more-targeted treatments, such as treatment directed at normalization of decreased inhibitory signaling through γ -aminobutyric acid (GABA) pathways, attributable to decreased GABA_A δ receptor activity in FXS.¹¹⁶ Treatment with neurosteroidal GABA receptor agonist anticonvulsants such as ganaxolone, which is used to treat infantile spasms,¹¹⁷ may be useful for epilepsy, anxiety, and aspects of cognition in FXS. Other potential target mechanisms of epileptogenesis operating in the absence of FMRP, such as overactivity of metabotropic glutamate receptor (mGluR)-mediated translation (see below) and indirect effects of altered α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor levels on *N*-methyl-D-aspartate receptor-evoked epileptiform potentials, may offer alternative therapeutic options in the future.¹¹⁸

After the choice of anticonvulsant, drug-specific blood and general health monitoring should be as indicated for any child taking these medications. It should be noted that, although immunization may be a time of risk for individuals predisposed to seizures, the epilepsy and autism risks in FXS are not contraindications to a standard immunization schedule.

NEUROBIOLOGICAL FEATURES AND TARGETED TREATMENTS

Neurobiological Findings

FMRP is a RNA-binding protein that modulates dendritic maturation and synaptic plasticity through a mechanism involving particularly the inhibition of group 1 mGluR-mediated dendritic protein synthesis.¹¹⁹⁻¹²² This concept is based in part on the finding that hippocampal and cerebellar long-term depression (ie, weakening of synaptic connections),¹²³ mediated by mGluR5 and mGluR1, respectively,¹²⁴ is enhanced in the *fmr1*-knockout mouse model of FXS (Fig 3). Furthermore, these forms of synaptic plasticity are not dependent on protein synthesis in knockout mice, which results in excessive translation of mRNAs normally bound by FMRP.¹²⁵ Numerous additional hypothesized consequences of excessive activity of mGluR-mediated processes are found in knockout mice, including reduced synaptic AMPA receptor levels and long-term potentiation deficits in the cortex¹²⁶ and hippocampus,¹²⁷ excessive internalization of AMPA receptors in cultured knockout mouse neurons,¹²⁸ immature-appearing, elongated den-dritic processes,^{119,120,129} and abnormal epileptiform discharges.¹³⁰ Furthermore, on the basis of known locations and activities of group 1 mGluR receptors in the nervous system, many phenotypic features of FXS, including seizures, electrical excitability on electroencephalograms, hypersensitivity to tactile stimuli, cognitive difficulties, strabismus, enhanced anxiety, coordination problems, and even loose stools, have been proposed to occur through enhancement of mGluR-mediated processes that normally would be inhibited by FMRP.¹³¹⁻¹³³

mGluR5 Antagonists

Many aspects of the phenotype in FXS animal models, including the behavioral abnormalities, cognitive deficits, and dendritic spine changes, are thought to be attributable to excessive mGluR5 signaling and can be rescued through genetic downregulation of mGluR5 expression, through crossing of *fmr1*-knockout mice with heterozygous mGluR5-knockout mice.¹³³ The only phenotypic aspect in knockout mice that is not rescued through this crossing is macroorchidism, in which the mGluR5 pathway likely is not involved.

It has been suggested that mGluR5 antagonists would be an effective treatment for FXS^{132, 133} (Fig 3). Selective mGluR5 antagonists have been available as research tools for nearly a decade,¹³⁴ and the prototype of the class, 2-methyl-6-(phenylethynyl)pyridine, has been tested extensively in animal models of FXS. 2-Methyl-6-(phenylethynyl)pyridine rescues the most robust central nervous system phenotypes in knockout mice, namely, hyperactivity and audiogenic seizure susceptibility.¹³⁵ It also has been shown to rescue cognitive and neuroanatomical phenotypes in a *Drosophila* (fruit fly) model of FXS,¹³⁶ as well as neurite branching and craniofacial abnormalities in zebrafish.¹³⁷

Although no mGluR5 antagonist has ever been marketed in any country,¹³⁸ there has been some published human experience with fenobam, a drug that was developed originally as an anxiolytic agent and was found to be a selective mGluR5 antagonist.¹³⁹ Investigational trials of fenobam (in non-FXS populations) showed it to be a very safe drug and a modestly effective anxiolytic agent.¹⁴⁰⁻¹⁴³ Fenobam is under development as an orphan drug for the treatment of FXS, with initial human FXS trials in 2008. Other mGluR5 antagonists are in development for a FXS indication, with clinical trials anticipated in the near future.

Because the pharmacologic spectrum of mGluR5 antagonists in animal models, that is, anxiolytic, antide-pressant, and anticonvulsant,^{144,145} is remarkably close to the neurobehavioral phenotype of FXS, these drugs have great potential for reversing or ameliorating many core features of the disorder. It is possible that some other developmental disorders, including other ASDs that may share pathophysiologic elements with FXS,¹⁰⁴ also may respond to treatment with this emerging drug class.

Lithium

Lithium is an alternative agent, currently available for use in humans, that downregulates the phospholipase C signaling pathway by inhibiting inositol phosphate turnover, thus attenuating phospholipase C enzyme activity.¹⁴⁶⁻¹⁴⁸ Because this pathway is used by mGluRs and other receptors to activate dendritic translation, its inhibition by lithium theoretically may correct excessive dendritic protein synthesis in FXS (Fig 3). Furthermore, lithium inhibits glycogen synthase kinase 3 β , which may downregulate mGluR-mediated translation of at least some proteins through additional pathways.¹⁴⁹ In fact, lithium was shown to improve defects in naive courtship behavior, as well as immediate recall and short-term memory, in the *Drosophila* model of FXS.¹³⁶ Lithium and other agents that block glycogen synthase kinase 3 β were shown to improve seizures in the knockout mouse model.¹⁴⁹ Berry-Kravis et al¹⁵⁰ conducted an add-on trial of lithium with 15 young male individuals (6–23 years of age) with FXS and found significant improvement in behavioral functioning, adaptive behavior, and verbal memory. The extracellular signal-regulated kinase activation rate, a potential biomarker for modulation of translational signaling through the phospholipase C cascade that is reduced in knockout mice and in patients with FXS, was normalized significantly with 2 months of lithium treatment. Results from that study suggested that lithium is well tolerated and may provide some functional benefits in FXS.

Ampakines

Although there has been much focus on the mGluR pathway as a treatment target in FXS, reduced AMPA receptor signaling and impaired cortical and hippocampal long-term potentiation^{126,127} represent other potential targets for pharmacologic intervention. A placebo-controlled clinical trial of the AMPA receptor positive modulator (ampakine) CX516 did not show improvements in behavioral or cognitive functioning in a cohort of subjects with FXS,¹⁵¹ although there was a suggestion of improvement for the small number of subjects treated with antipsychotic agents (which potentiate the effects of ampakines) and active drug, compared with placebo. This finding, combined with emerging data from other trials and pharmacologic work, suggested that CX516 is an agent with low potency that does not induce synaptic changes (increases in brain-derived neurotrophic factor [BDNF] levels) as effectively as other ampakine compounds and was likely being used at subtherapeutic doses. Lauterborn et al¹²⁷ showed recently that BDNF fully rescued hippocampal long-term potentiation deficits in *fmr1*-knockout mice; therefore, an appropriately therapeutic ampakine with good capability for induction of endogenous BDNF production¹⁵² would be a good candidate to target at least part of the underlying mechanism of abnormal synaptic plasticity in FXS.

BEHAVIORAL INTERVENTIONS

Despite the wealth of knowledge regarding the behavioral phenotype of FXS, there are almost no empirical studies on the effectiveness of behavioral treatments among patients with FXS.¹⁵³ Obviously, the lack of treatment studies severely restricts the empirically validated behavioral treatment recommendations that can be made to patients with FXS and their families. Providers generally have relied on their own clinical experience and an understanding of the aforementioned factors shown to be associated with behavioral problems in phenotype studies to guide treatment approaches. The lack of empirical treatment studies in the FXS field

is ironic, given that several research projects have highlighted the fact that challenging behaviors of these individuals seem to have the greatest impact on parents and families, greater than that of cognitive impairment.¹⁵⁴

Both animal and human studies have shown that variations in the environment have an impact on behavior.¹⁵⁵ For example, a higher-quality home environment is associated with fewer autistic behaviors, better adaptive behavior, and higher IQ scores in children with FXS.^{156, 157} Effectiveness of educational services, as reported by parents, also has been associated with better behavioral outcomes and fewer autistic behaviors.¹⁵⁸ Those studies suggest that modifications in the home environment and more-tailored behavioral interventions and classroom environments should lead to better outcomes for children with FXS, but this overly general suggestion has not been tested with specific interventions. Similarly, the findings that children with FXS have heightened electrodermal responses to sensory stimuli⁵² and elevated stress hormone levels, which are related to the severity of behavioral and social problems,^{159,160} suggest that interventions aimed at reduction of and better coping with stress and sensory input should result in better outcomes, but no treatment studies have been performed to document this. Reiss and Hall,¹⁵³ in their review of the assessment and treatment of FXS, provided examples of novel behavior modification interventions aimed at improving social eye contact and stress reduction and supported treatment models that combine behavioral interventions with experimental pharmacologic or hormonal treatments that are supported by laboratory data. Studies comparing behavioral, targeted pharmacologic, and combined approaches are needed.

Although large behavioral treatment studies of individuals with FXS are difficult, well-designed, multiple-baseline, individual-subject studies are quite feasible and can yield convincing accounts of efficacy with relatively few participants. Weiskop et al,¹⁶¹ in the only empirical FXS behavioral treatment study in the literature, used such a design to investigate a parent training program to reduce sleep problems in children with autism ($N = 6$) or FXS ($N = 5$). Although the study was small, the program seemed generally successful; the study provides a good model for other multiple-baseline studies that could be performed, focusing on aggression, self-injury, and other maladaptive behaviors.

A detailed review and recommendations for behavioral treatment of individuals with FXS were provided by Hills-Epstein et al.¹⁶² Those recommendations, which generally follow principles of functional behavioral analysis and the antecedent-behavior-consequence model, are based on sound principles of how maladaptive behaviors are maintained and rewarded and how they can be replaced through positive reinforcement of appropriate or adaptive behaviors.

The state of the science in psychosocial treatment through behavioral interventions in ASDs was reviewed comprehensively by a National Institutes of Health-sponsored panel of national experts on autism.¹⁶³ That review offers important insights and recommendations that are applicable to behavioral treatment of individuals with FXS, because of the very high rates of autism and autistic behaviors. The authors emphasized that the traditional 1-hour/week treatments for language, social skills, or behavior that are used in the US mental health and educational systems are rarely sufficient to lead to generalized improvements for children with autism. This statement probably also reflects the needs of children with FXS, with or without autism. The unique factors likely to be contributing to maladaptive behaviors in FXS (ie, anxiety, sensory overload, and inattention/impulsivity) would need to be fully appreciated by an equivalently trained behavioral intervention team. There are several treatment models, including the Treatment and Education of Autistic and Related Communication-Handicapped Children model,¹⁶⁴ the Denver model,¹⁶⁵ pivotal response training,¹⁶⁶ and applied behavior analysis,¹⁶⁷ that are well established in autism treatment. These models, or aspects of these models, should be applied to groups of individuals with FXS or with FXS and autism, to test

their efficacy. In our clinical experience, these treatment programs have been helpful for many children with FXS and ASD.

Higher-functioning individuals with FXS can benefit from psychotherapy or counseling.^{162, 168} This work can focus on anxiety reduction through desensitization, sexuality issues, management of depression (usually through structured cognitive behavioral approaches), and socialization issues. Many individuals with FXS who have autistic symptoms and social anxiety also can benefit from social skills-oriented group therapy.¹⁶⁸ A program to address behavioral problems and sexuality issues in adolescence and young adulthood was developed recently by the National Fragile X Foundation, to guide professionals and family members.

GENETIC COUNSELING

When an individual is identified as being at risk for FXS, it is imperative that the clinician explains to the family the indications for testing. If the testing results are positive, then referral to a geneticist and/or a genetic counselor is recommended, so that the appropriate clinician can interpret the results for the family according to the guidelines for FXS established by the National Society of Genetic Counselors and the American Society of Human Genetics.^{35,169, 170} The genetic counselor will review the inheritance pattern for FXS, which should enable identification of individuals at risk for carrying *FMR1* mutations and should help the family in developing an appropriate strategy regarding how information is conveyed to other family members.¹⁷¹ This may involve personal contact between family members or an informational letter, or the family may choose to have the genetic counselor, geneticist, or pediatrician meet with members of the extended family, to discuss the diagnosis of FXS and FX-associated conditions and to facilitate testing for family members who are at risk.

The counselor also can review reproductive options for future pregnancies, including egg donation, prenatal diagnosis, adoption, and preimplantation genetic diagnosis through polar body analysis.^{35,172,173} Emotional, endocrinologic, and neurologic problems need to be reviewed for all extended family members at risk for either the premutation or the full mutation.³⁵ Individuals who have symptoms of involvement should be tested, as well as their siblings. Positive test results for siblings often help to mobilize treatment even for mild problems (eg, ADHD or anxiety). Newly diagnosed families should be connected to local parent support groups, which can be found with the advocacy groups listed in the Appendix.

SCREENING FOR FXS

High-risk testing for FXS is recommended for individuals with autism, ASD, or intellectual disability.^{34,35} In addition, screening is recommended for individuals with features of FXS and learning disabilities, women with primary ovarian insufficiency, and aging adults with ataxia or tremor combined with other features of FXTAS or a family history consistent with FXS.^{35,44,174} Several studies have assessed broader population screening, including prenatal screening¹⁷⁵⁻¹⁷⁷ and screening of populations with neurologic conditions.^{178,179} Newborn screening for FXS is currently being researched in multiple locations in the United States, in line with the broadening of newborn screening criteria to include neurodevelopmental disorders that would benefit from early intervention.^{173,180} Many children with FXS receive late diagnoses, and as many as 50% of parents have had another child or pregnancy before the diagnosis, without the opportunity for counseling and informed decision-making before the subsequent pregnancy.¹⁸¹⁻¹⁸³ One impediment to widespread screening has been the cost of the *FMR1* DNA test. Less-expensive screening methods have been developed.^{184,185} The blood spot test described by Tassone et al¹⁸⁵ substantially reduces the cost of screening, to less than \$5 per test, and screens for the full mutation and the premutation in both genders. If screening test results are positive, then follow-up definitive DNA testing for FXS, including Southern blotting, is recommended.¹⁸⁵ The availability of this test, and perhaps other tests in

the future, will likely facilitate expansion of newborn screening and the screening of high-risk populations.

CONCLUSIONS

We are entering a new age of targeted treatments for FXS and more-widespread screening for this disorder. Therefore, it is likely that most pediatricians or medical providers will encounter ≥ 1 patient affected by FXS or the premutation in their practices. Multidisciplinary treatment, including speech and language therapy, occupational therapy, physical therapy, special education, behavioral interventions, and genetic counseling, can be coordinated by the pediatrician, who also adds the medical interventions reviewed here. As newborn screening develops, early intervention for infants can be coordinated by the pediatrician or family care provider, working with an early intervention team. New targeted treatments for FXS are emerging, and older treatments (such as lithium) also can target the mGluR5 pathway abnormalities in FXS. Extended involvement in multiple family members is common, because several medical problems affect premutation carriers, in addition to a broad spectrum of involvement in individuals with the full mutation. Therefore, pediatricians should consider extended family DNA testing, with the help of a genetic counselor or geneticist, and follow-up care with a multidisciplinary treatment team.

Acknowledgments

This work was supported by the National Fragile X Foundation, National Institutes of Health grants HD036071, HD02274, AG032115, DE019583, and RR024146, and Administration of Developmental Disabilities Center of Excellence in Developmental Disabilities grant 90DD0596 (Dr Hagerman), National Institute of Child Health and Human Development grant HD24061 (Dr Kaufmann), National Institutes of Health/National Center for Research Resources grants 5K12RR017643 and 1KL2RR025009 (Dr Visootsak), the Spastic Paralysis and Allied Diseases of the Central Nervous System Research Foundation of the Illinois-Eastern Iowa District of Kiwanis International (Dr Berry-Kravis), National Institute of Mental Health grant MH77554 (Dr Hessler), and the FRAXA Research Foundation (Dr Tranfaglia).

APPENDIX: FXS RESOURCES

National Fragile X Foundation, PO Box 37, Walnut Creek, CA, 94597. Telephone: 800-688-8765, 925-938-9300; fax: 925-938-9315; natlfx@fragilex.org; Internet: www.fragilex.org

FRAXA Research Foundation, 45 Pleasant St, Newburyport, MA 01950. Telephone: 978-462-1866; fax: 978-463-9985; info@fraxa.org; Internet: www.fraxa.org

National Institute of Child Health and Human Development, PO Box 3006, Rockville, MD 20847. Telephone: 1-800-370-2943; fax: 866-760-5947; nichdinformationresourcecenter@mail.nih.gov; Internet: www.nichd.nih.gov

Dolan DNA Learning Center: Your Genes Your Health. Internet: www.ygyh.org

GeneTests. Internet: www.geneclinics.org

Abbreviations

ADHD	attention-deficit/hyperactivity disorder
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ASD	autism spectrum disorder
BDNF	brain-derived neurotrophic factor

CYFIP1	cytoplasmic <i>FMRI</i> -interacting protein 1
FMRP	fragile X mental retardation protein
FXS	fragile X syndrome
FXTAS	fragile X-associated tremor/ataxia syndrome
GABA	γ -aminobutyric acid
mGluR	metabotropic glutamate receptor
PWP	Prader-Willi phenotype
SSRI	selective serotonin reuptake inhibitor

REFERENCES

1. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. *Ment Retard Dev Disabil Res Rev* 2004;10(1):31–41. [PubMed: 14994286]
2. Tassone F, Hagerman RJ, Iklé DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am J Med Genet* 1999;84(3):250–261. [PubMed: 10331602]
3. Pieretti M, Zhang FP, Fu YH, et al. Absence of expression of the *FMR-1* gene in fragile X syndrome. *Cell* 1991;66(4):817–822. [PubMed: 1878973]
4. De Boulle K, Verkerk AJ, Reyniers E, et al. A point mutation in the *FMR-1* gene associated with fragile X mental retardation. *Nat Genet* 1993;3(1):31–35. [PubMed: 8490650]
5. Coffee B, Ikeda M, Budimirovic DB, Hjelm LN, Kaufmann WE, Warren ST. Mosaic *FMRI* deletion causes fragile X syndrome and can lead to molecular misdiagnosis. *Am J Med Genet A* 2008;146A(10):1358–1367. [PubMed: 18412117]
6. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the *FMRI* premutation. *Am J Med Genet* 2000;91(2):144–152. [PubMed: 10748416]
7. Crawford DC, Meadows KL, Newman JL, et al. Prevalence of the fragile X syndrome in African-Americans. *Am J Med Genet* 2002;110(3):226–233. [PubMed: 12116230]
8. Sherman S. Epidemiology. In: Hagerman, RJ.; Hagerman, PJ., editors. *Fragile X Syndrome: Diagnosis, Treatment, and Research*. 3rd ed.. Johns Hopkins University Press; Baltimore, MD: 2002. p. 136-168.
9. Dawson AJ, Chodirker BN, Chudley AE. Frequency of *FMRI* premutations in a consecutive newborn population by PCR screening of Guthrie blood spots. *Biochem Mol Med* 1995;56(1):63–69. [PubMed: 8593539]
10. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the *FMRI* gene and implications for the population genetics of the fragile X syndrome. *Am J Hum Genet* 1995;57(5):1006–1018. [PubMed: 7485149]
11. Dombrowski C, Levesque ML, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size *FMRI* alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. *Hum Mol Genet* 2002;11(4):371–378. [PubMed: 11854169]
12. Hagerman PJ. The fragile X prevalence paradox. *J Med Genet* 2008;45(8):498–499. [PubMed: 18413371]
13. Kenneson A, Zhang F, Hagedorn CH, Warren ST. Reduced FMRP and increased *FMRI* transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. *Hum Mol Genet* 2001;10(14):1449–1454. [PubMed: 11448936]
14. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of *FMRI* mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. *Am J Hum Genet* 2000;66(1):6–15. [PubMed: 10631132]

15. Kaufmann WE, Abrams MT, Chen W, Reiss AL. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. *Am J Med Genet* 1999;83(4):286–295. [PubMed: 10208163]
16. Reiss AL, Dant CC. The behavioral neurogenetics of fragile X syndrome: analyzing gene-brain-behavior relationships in child developmental psychopathologies. *Dev Psychopathol* 2003;15(4):927–968. [PubMed: 14984133]
17. de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an *FMR1* gene full mutation. *Am J Hum Genet* 1996;58(5):1025–1032. [PubMed: 8651263]
18. Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. *Am J Med Genet B Neuropsychiatr Genet* 2003;121B(1):119–127. [PubMed: 12898586]
19. Loesch DZ, Bui MQ, Grigsby J, et al. Effect of the fragile X status categories and the FMRP levels on executive functioning in fragile X males and females. *Neuropsychology* 2003;17(4):646–657. [PubMed: 14599277]
20. Moore CJ, Daly EM, Schmitz N, et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. *Neuropsychologia* 2004;42(14):1934–1947. [PubMed: 15381024]
21. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. *J Dev Behav Pediatr* 2006;27(2 suppl):S137–S144. [PubMed: 16685180]
22. Hessl D, Tassone F, Loesch DZ, et al. Abnormal elevation of *FMR1* mRNA is associated with psychological symptoms in individuals with the fragile X premutation. *Am J Med Genet B Neuropsychiatr Genet* 2005;139B(1):115–121. [PubMed: 16184602]
23. Goodlin-Jones B, Tassone F, Gane LW, Hagerman RJ. Autistic spectrum disorder and the fragile X premutation. *J Dev Behav Pediatr* 2004;25(6):392–398. [PubMed: 15613987]
24. Cornish KM, Kogan C, Turk J, et al. The emerging fragile X premutation phenotype: evidence from the domain of social cognition. *Brain Cogn* 2005;57(1):53–60. [PubMed: 15629215]
25. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. *Am J Hum Genet* 2004;74(5):805–816. [PubMed: 15052536]
26. Allen EG, He W, Yadav-Shah M, Sherman SL. A study of the distributional characteristics of *FMR1* transcript levels in 238 individuals. *Hum Genet* 2004;114(5):439–447. [PubMed: 14758538]
27. Sullivan AK, Marcus M, Epstein MP, et al. Association of *FMR1* repeat size with ovarian dysfunction. *Hum Reprod* 2005;20(2):402–412. [PubMed: 15608041]
28. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA* 2004;291(4):460–469. [PubMed: 14747503]
29. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the *FMR1* premutation. *Am J Med Genet A* 2008;146A(8):1009–1016. [PubMed: 18348275]
30. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of *FMR1*. *Lancet Neurol* 2007;6(1):45–55. [PubMed: 17166801]
31. Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the *FMR1* premutation. *Mov Disord* 2007;22(2):203–206. [PubMed: 17133502]
32. Hagerman RJ, Coffey SM, Maselli R, et al. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. *Am J Med Genet A* 2007;143A(19):2256–2260. [PubMed: 17726686]
33. Willemsen R, Mientjes E, Oostra BA. FXTAS: a progressive neurologic syndrome associated with fragile X premutation. *Curr Neurol Neurosci Rep* 2005;5(5):405–410. [PubMed: 16131424]
34. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. *J Dev Behav Pediatr* 2006;27(1):63–74. [PubMed: 16511373]
35. McConkie-Rosell A, Abrams L, Finucane B, et al. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. *J Genet Couns* 2007;16(5):593–606. [PubMed: 17497108]
36. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. *Clin Interv Aging* 2008;3(2):251–262. [PubMed: 18686748]

37. Hagerman, RJ. Medical follow-up and pharmacotherapy. In: Hagerman, RJ.; Hagerman, PJ., editors. *Fragile X Syndrome: Diagnosis, Treatment, and Research*. 3rd ed.. Johns Hopkins University Press; Baltimore, MD: 2002. p. 287-338.
38. Hatton DD, Buckley EG, Lachiewicz A, Roberts J. Ocular status of young boys with fragile X syndrome: a prospective study. *J AAPOS* 1998;2(5):298–302. [PubMed: 10646752]
39. Hagerman RJ, Altshul-Stark D, McBogg P. Recurrent otitis media in boys with the fragile X syndrome. *Am J Dis Child* 1987;141(2):184–187. [PubMed: 3812386]
40. Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. *J Bone Joint Surg Am* 1990;72(6):889–896. [PubMed: 2195034]
41. Hagerman, RJ. Physical and behavioral phenotype. In: Hagerman, RJ.; Hagerman, PJ., editors. *Fragile X Syndrome: Diagnosis, Treatment, and Research*. 3rd ed.. Johns Hopkins University Press; Baltimore, MD: 2002. p. 3-109.
42. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. *J Pediatr Gastroenterol Nutr* 2001;32(suppl 2):S1–S31. [PubMed: 11525610]
43. King RA, Hagerman RJ, Houghton M. Ocular findings in fragile X syndrome. *Dev Brain Dysfunct* 1995;8:223–229.
44. Wittenberger MD, Hagerman RJ, Sherman SL, et al. The *FMR1* premutation and reproduction. *Fertil Steril* 2007;87(3):456–465. [PubMed: 17074338]
45. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. *Pediatrics* 1995;95(5):744–752. [PubMed: 7724315]
46. Roberts JE, Boccia ML, Bailey DB, Hatton D, Skinner M. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. *Dev Psychobiol* 2001;39(2):107–123. [PubMed: 11568881]
47. Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. *Am J Med Genet A* 2006;140A(17):1804–1813. [PubMed: 16700053]
48. Turk J. Fragile X syndrome and attentional deficits. *J Appl Res Intellect Disabil* 1998;11:175–191.
49. Cornish KM, Turk J, Wilding J, et al. Annotation: deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach. *J Child Psychol Psychiatry* 2004;45(6):1042–1053. [PubMed: 15257661]
50. Chiu S, Wegelin JA, Blank J, et al. Early acceleration of head circumference in children with fragile X syndrome and autism. *J Dev Behav Pediatr* 2007;28(1):31–35. [PubMed: 17353729]
51. Kau ASM, Tierney E, Bukelis I, et al. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. *Am J Med Genet A* 2004;126A(1):9–17. [PubMed: 15039968]
52. Miller LJ, McIntosh DN, McGrath J, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. *Am J Med Genet* 1999;83(4):268–279. [PubMed: 10208160]
53. Cohen IL, Fisch GS, Sudhalter V, et al. Social gaze, social avoidance, and repetitive behavior in fragile X males: a controlled study. *Am J Ment Retard* 1988;92(5):436–446. [PubMed: 2965890]
54. Sullivan K, Hatton D, Hammer J, et al. ADHD symptoms in children with FXS. *Am J Med Genet A* 2006;140(21):2275–2288. [PubMed: 17022076]
55. Lachiewicz AM, Dawson DV, Spiridigliozzi GA, McConkie-Rosell A. Arithmetic difficulties in females with the fragile X premutation. *Am J Med Genet A* 2006;140(7):665–672. [PubMed: 16508954]
56. Mazzocco MM, Singh Bhatia N, Lesniak-Karpiak K. Visuospatial skills and their association with math performance in girls with fragile X or Turner syndrome. *Child Neuropsychol* 2006;12(2):87–110. [PubMed: 16754531]
57. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. *Pediatrics* 1993;91(2):321–329. [PubMed: 8380924]
58. Angkustsiri K, Wirojanan J, Deprey L, Gane LW, Hagerman RJ. Fragile X syndrome with anxiety disorder and exceptional verbal intelligence. *Am J Med Genet A* 2008;146(3):376–379. [PubMed: 18203169]

59. Bailey DB Jr, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile X syndrome. *J Autism Dev Disord* 1998;28(6):499–508. [PubMed: 9932236]
60. Kaufmann WE, Cortell R, Kau AS, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. *Am J Med Genet A* 2004;129A(3):225–234. [PubMed: 15326621]
61. Rogers SJ, Wehner EA, Hagerman RJ. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. *J Dev Behav Pediatr* 2001;22(6):409–417. [PubMed: 11773805]
62. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. *J Autism Dev Disord* 2007;37(4):738–747. [PubMed: 17031449]
63. Loesch DZ, Bui QM, Dissanayake C, et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. *Neurosci Biobehav Rev* 2007;31(3):315–326. [PubMed: 17097142]
64. Hagerman RJ, Rivera SM, Hagerman PJ. The fragile X family of disorders: a model for autism and targeted treatments. *Curr Pediatr Rev* 2008;4(1):40–52.
65. Bailey DB Jr, Hatton DD, Skinner M, Mesibov GB. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. *J Autism Dev Disord* 2001;31(2):165–174. [PubMed: 11450815]
66. Hatton D, Hooper SR, Bailey DB, Skinner ML, Sullivan KM, Wheeler A. Problem behavior in boys with fragile X syndrome. *Am J Med Genet* 2002;108(2):105–116. [PubMed: 11857559]
67. Sabaratnam M, Murthy NV, Wijeratne A, Buckingham A, Payne S. Autistic-like behaviour profile and psychiatric morbidity in fragile X syndrome: a prospective ten-year follow-up study. *Eur Child Adolesc Psychiatry* 2003;12(4):172–177. [PubMed: 14505067]
68. Roberts JE, Schaaf JM, Skinner M, et al. Academic skills of boys with fragile X syndrome: profiles and predictors. *Am J Ment Retard* 2005;110(2):107–120. [PubMed: 15762821]
69. Backes M, Genç B, Schreck J, Doerfler W, Lehmkuhl G, Gontard A. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. *Am J Med Genet* 2000;95(2):150–156. [PubMed: 11078566]
70. Borghgraef M, Fryns JP, Dielkens A, Pyck K, Van den Berghe H. Fragile X syndrome: a study of the psychological profile in 23 prepubertal patients. *Clin Genet* 1987;32(3):179–186. [PubMed: 3621665]
71. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention deficits in young males with fragile X syndrome. *Neuropsychologia* 2000;38(9):1261–1270. [PubMed: 10865102]
72. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. *Am J Med Genet* 1988;30(1–2):377–392. [PubMed: 3052064]
73. Amaria RN, Billeisen LL, Hagerman RJ. Medication use in fragile X syndrome. *Ment Health Asp Dev Disabil* 2001;4(4):143–147.
74. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome: present and future. *Ment Retard Dev Disabil Res Rev* 2004;10(1):42–48. [PubMed: 14994287]
75. Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. Influence of stimulants on electrodermal studies in fragile X syndrome. *Microsc Res Tech* 2002;57(3):168–173. [PubMed: 12112453]
76. Hagerman RJ, Riddle JE, Roberts LS, Brease K, Fulton M. A survey of the efficacy of clonidine in fragile X syndrome. *Dev Brain Dysfunct* 1995;8(4–6):336–344.
77. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders: a case series. *Eur Child Adolesc Psychiatry* 2005;14(1):34–40. [PubMed: 15756514]
78. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in treatment of attention deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1995;34(1):50–54. [PubMed: 7860456]
79. Horrigan J, Barnhill L. Guanfacine for treatment of attention-deficit hyperactivity disorder. *J Child Adolesc Psychopharmacol* 1995;5(3):215–223.
80. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. *Am J Psychiatry* 2001;158(7):1067–1074. [PubMed: 11431228]

81. Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. α_2 -Adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. *Pediatr Clin North Am* 1998;45(5):1099–1122. [PubMed: 9884677]
82. Torrioli MG, Vernacotola S, Peruzzi L, et al. A double-blind, parallel, multicenter comparison of l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. *Am J Med Genet A* 2008;146(7):803–812. [PubMed: 18286595]
83. Torrioli MG, Vernacotola S, Mariotti P, et al. Double-blind, placebo-controlled study of l-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome [letter]. *Am J Med Genet* 1999;87(4):366–368. [PubMed: 10588848]
84. Hagerman RJ, Fulton MJ, Leaman A, Riddle J, Hagerman K, Sobesky W. A survey of fluoxetine therapy in fragile X syndrome. *Dev Brain Dysfunct* 1994;7:155–164.
85. Hagerman RJ, Hills J, Scharfenaker S, Lewis H. Fragile X syndrome and selective mutism. *Am J Med Genet* 1999;83(4):313–317. [PubMed: 10208168]
86. Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. *J Child Adolesc Psychopharmacol* 2006;16(1–2):187–195. [PubMed: 16553539]
87. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. *J Autism Dev Disord* 2000;30(5):427–435. [PubMed: 11098879]
88. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am* 2006;15(1):161–175. [PubMed: 16321729]
89. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. *J Autism Dev Disord* 2003;33(1):77–85. [PubMed: 12708582]
90. Erickson CA, Posey DJ, Stigler KA, McDougle CJ. Pharmacologic treatment of autism and related disorders. *Pediatr Ann* 2007;36(9):575–585. [PubMed: 17910205]
91. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. *Dev Med Child Neurol* 2002;44(10):652–659. [PubMed: 12418789]
92. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. *Neuropsychopharmacology* 2005;30(3):582–589. [PubMed: 15602505]
93. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. *J Pediatr* 2006;148(2):158–165. [PubMed: 16492422]
94. Hessler D, Tassone F, Cordeiro L, et al. Brief report: aggression and stereotypic behavior in males with fragile X syndrome: moderating secondary genes in a “single gene” disorder. *J Autism Dev Disord* 2008;38(1):184–189. [PubMed: 17340199]
95. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347(5):314–321. [PubMed: 12151468]
96. Berry-Kravis, E.; Sumis, A. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome; Presented at the 10th International Fragile X Conference; Atlanta, GA. July 19–23, 2006;
97. Li M, Budin R, Fleming AS, Kapur S. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. *Psychopharmacology (Berl)* 2005;181(3):600–610. [PubMed: 16025315]
98. Fryns J, Haspeslagh M, Dereymaeker A, Volcke P, Van den Berghe H. A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation: further evidence of disturbed hypothalamic function in the fra(X) syndrome? *Clin Genet* 1987;32(6):388–392. [PubMed: 3436088]
99. de Vries BB, Fryns JP, Butler MG, et al. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. *J Med Genet* 1993;30(9):761–766. [PubMed: 8411072]

100. Schrander-Stumpel C, Gerver W-T, Meyer H, Engelen J, Mulder H, Fryns J-P. Prader-Willi-like phenotype in fragile X syndrome. *Clin Genet* 1994;45(4):175–180. [PubMed: 8062434]
101. Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. *J Dev Behav Pediatr* 2007;28(2):133–138. [PubMed: 17435464]
102. Chai JH, Locke DP, Greally JM, et al. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. *Am J Hum Genet* 2003;73(4):898–925. [PubMed: 14508708]
103. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. CYFIP/Sra-1 controls neuronal connectivity in *Drosophila* and links the Rac1 GTPase pathway to the fragile X protein. *Neuron* 2003;38(6):887–898. [PubMed: 12818175]
104. Nishimura Y, Martin CL, Vazquez-Lopez A, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. *Hum Mol Genet* 2007;16(14):1682–1698. [PubMed: 17519220]
105. Chen C, Visootsak J, Dills S, Graham JM Jr. Prader-Willi syndrome: an update and review for the primary pediatrician. *Clin Pediatr (Phila)* 2007;46(7):580–591. [PubMed: 17522286]
106. Forster, J.; Gourash, L. Food Security. Pittsburgh Partnership; Pittsburgh, PA: 2005.
107. Balko, K. Red, Yellow, Green System for Weight Management. Prader-Willi Syndrome Association; Sarasota, FL: 2005.
108. Ribacoba Montero R, Salas Puig J, Fernández Toral J, Fernán-dez Martínez JM, Moral Rato M. Fragile X syndrome and epilepsy [in Spanish]. *Neurologia* 1995;10(2):70–75. [PubMed: 7695946]
109. Sabaratnam M, Vroegop PG, Gangadharan SK. Epilepsy and EEG findings in 18 males with fragile X syndrome. *Seizure* 2001;10(1):60–63. [PubMed: 11181100]
110. Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. *Epilepsia* 1999;40(8):1092–1099. [PubMed: 10448821]
111. Berry-Kravis E. Epilepsy in fragile X syndrome. *Dev Med Child Neurol* 2002;44(11):724–728. [PubMed: 12418611]
112. Incorpora G, Sorge G, Sorge A, Pavone L. Epilepsy in fragile X syndrome. *Brain Dev* 2002;24(8):766–769. [PubMed: 12453600]
113. Musumeci SA, Ferri R, Elia M, Colognola RM, Bergonzi P, Tassinari CA. Epilepsy and fragile X syndrome: a follow-up study. *Am J Med Genet* 1991;38(2–3):511–513. [PubMed: 2018098]
114. Rees M, Diebold U, Parker K, Doose H, Gardiner RM, White-house WP. Benign childhood epilepsy with centrotemporal spikes and the focal sharp wave trait is not linked to the fragile X region. *Neuropediatrics* 1993;24(4):211–213. [PubMed: 8232779]
115. García-Nonell C, Ratera ER, Harris SW, et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. *Am J Med Genet A* 2008;146A(15):1911–1916. [PubMed: 18627038]
116. D’Hulst C, Kooy RF. The GABA_A receptor: a novel target for treatment of fragile X? *Trends Neurosci* 2007;30(8):425–431. [PubMed: 17590448]
117. Rogawski, MA.; Reddy, DS. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho, JM.; Sankar, R.; Cavazos, J., editors. *Epilepsy: Scientific Foundations of Clinical Practice*. Marcel Dekker; New York, NY: 2004. p. 319-355.
118. Addae JJ, Ali N, Youssef FF, Stone TW. AMPA receptor activation reduces epileptiform activity in the rat neocortex. *Brain Res* 2007;1158:151–157. [PubMed: 17543292]
119. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. *Nat Rev Neurosci* 2005;6(5):376–387. [PubMed: 15861180]
120. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond. *J Neurosci* 2006;26(27):7151–7155. [PubMed: 16822971]
121. Weiler IJ, Spangler CC, Klintsova AY, et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. *Proc Natl Acad Sci U S A* 2004;101(50):17504–17509.

122. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. *Proc Natl Acad Sci U S A* 2005;102(6):2180–2185. [PubMed: 15684045]
123. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci U S A* 2002;99(11):7746–7750. [PubMed: 12032354]
124. Koekkoek SK, Yamaguchi K, Milojkovic BA, et al. Deletion of *FMR1* in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. *Neuron* 2005;47(3):339–352. [PubMed: 16055059]
125. Nosyreva ED, Huber KM. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. *J Neurophysiol* 2006;95(5):3291–3295. [PubMed: 16452252]
126. Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. *Mol Cell Neurosci* 2002;19(2):138–151. [PubMed: 11860268]
127. Lauterborn JC, Rex CS, Kramar E, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. *J Neurosci* 2007;27(40):10685–10694. [PubMed: 17913902]
128. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. *Proc Natl Acad Sci U S A* 2007;104(39):15537–15542. [PubMed: 17881561]
129. Irwin SA, Idupulapati M, Gilbert ME, et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. *Am J Med Genet* 2002;111(2):140–146. [PubMed: 12210340]
130. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. *J Neurosci* 2005;25(35):8048–8055. [PubMed: 16135762]
131. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci* 2004;27(7):370–377. [PubMed: 15219735]
132. Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. *Genes Brain Behav* 2005;4(6):393–398. [PubMed: 16098137]
133. Dölen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. *Neuron* 2007;56(6):955–962. [PubMed: 18093519]
134. Gasparini F, Lingenhohl K, Stoehr N, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. *Neuropharmacology* 1999;38(10):1493–1503. [PubMed: 10530811]
135. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology* 2005;49(7):1053–1066. [PubMed: 16054174]
136. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a *Drosophila* model of fragile X syndrome. *Neuron* 2005;45(5):753–764. [PubMed: 15748850]
137. Tucker B, Richards RI, Lardelli M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. *Hum Mol Genet* 2006;15(23):3446–3458. [PubMed: 17065172]
138. Slassi A, Isaac M, Edwards L, et al. Recent advances in noncompetitive mGlu5 receptor antagonists and their potential therapeutic applications. *Curr Top Med Chem* 2005;5(9):897–911. [PubMed: 16178734]
139. Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. *J Pharmacol Exp Ther* 2005;315(2):711–721. [PubMed: 16040814]

140. Itil T, Seaman P, Huque M, et al. The clinical and quantitative EEG effects and plasma levels of fenbam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. *Curr Ther Res* 1978;24(6):708–724.
141. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenbam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. *J Clin Psychopharmacol* 1982;2(2):129–133. [PubMed: 7042771]
142. Friedmann C, Davis L, Ciccone P, Rubin R. Phase II double-blind controlled study of a new anxiolytic, fenbam (McN-3377) vs placebo. *Curr Ther Res* 1980;27(2):144–151.
143. LaPierre Y, Oyewumi L. Fenbam: another anxiolytic? *Curr Ther Res* 1982;31(1):95–101.
144. Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. *J Pharmacol Exp Ther* 2000;295(3):1267–1275. [PubMed: 11082464]
145. Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. *Br J Pharmacol* 2001;132(7):1423–1430. [PubMed: 11264235]
146. Berridge MJ. The Albert Lasker Medical Awards: inositol trisphosphate, calcium, lithium, and cell signaling. *JAMA* 1989;262(13):1834–1841. [PubMed: 2674489]
147. Takei K, Shin RM, Inoue T, Kato K, Mikoshiba K. Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. *Science* 1998;282(5394):1705–1708. [PubMed: 9831561]
148. Larsen GA, Berg-Johnsen J, Moe MC, Vinje ML. Calcium-dependent protein kinase C activation in acutely isolated neurons during oxygen and glucose deprivation. *Neurochem Res* 2004;29(10):1931–1937. [PubMed: 15532549]
149. Bauchwitz, R. GSK3 inhibitors and mGluR5 antagonists can produce an additive rescue of fragile X mouse phenotypes; Presented at the 10th International Fragile X Conference; Atlanta, GA. July 19–23, 2006;
150. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. *J Dev Behav Pediatr* 2008;29(4):293–302. [PubMed: 18698192]
151. Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. *J Child Adolesc Psychopharmacol* 2006;16(5):525–540. [PubMed: 17069542]
152. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. *J Neurosci* 2000;20(1):8–21. [PubMed: 10627576]
153. Reiss AL, Hall SS. Fragile X syndrome: assessment and treatment implications. *Child Adolesc Psychiatr Clin N Am* 2007;16(3):663–675. [PubMed: 17562585]
154. Bailey DB Jr, Skinner D, Hatton D, Roberts J. Family experiences and factors associated with the diagnosis of fragile X syndrome. *J Dev Behav Pediatr* 2000;21(5):315–321. [PubMed: 11064958]
155. Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. *Proc Natl Acad Sci U S A* 2005;102(32):11557–11562. [PubMed: 16076950]
156. Glaser B, Hessel D, Dyer-Friedman J, et al. Biological and environmental contributions to adaptive behavior in fragile X syndrome. *Am J Med Genet A* 2003;117A(1):21–29. [PubMed: 12548736]
157. Dyer-Friedman J, Glaser B, Hessel D, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. *J Am Acad Child Adolesc Psychiatry* 2002;41(3):237–244. [PubMed: 11886017]
158. Hessel D, Dyer-Friedman J, Glaser B, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. *Pediatrics* 2001;108(5) Available at: www.pediatrics.org/cgi/content/full/108/5/e88.
159. Hessel D, Glaser B, Dyer-Friedman J, Reiss AL. Social behavior and cortisol reactivity in children with fragile X syndrome. *J Child Psychol Psychiatry* 2006;47(6):602–610. [PubMed: 16712637]
160. Hessel D, Glaser B, Dyer-Friedman J, et al. Cortisol and behavior in fragile X syndrome. *Psychoneuroendocrinology* 2002;27(7):855–872. [PubMed: 12183220]

161. Weiskop S, Richdale A, Matthews J. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. *Dev Med Child Neurol* 2005;47(2):94–104. [PubMed: 15707232]
162. Hills-Epstein, J.; Riley, K.; Sobesky, W. The treatment of emotional and behavioral problems. In: Hagerman, RJ.; Hagerman, PJ., editors. *Fragile X Syndrome: Diagnosis, Treatment, and Research*. 3rd ed.. Johns Hopkins University Press; Baltimore, MD: 2002. p. 339-362.
163. Lord C, Wagner A, Rogers S, et al. Challenges in evaluating psychosocial interventions for autistic spectrum disorders. *J Autism Dev Disord* 2005;35(6):695–708. [PubMed: 16496206]
164. Schopler, E.; Mesibov, G.; Shigley, R.; Bashford, A. Helping autistic children through their parents: the TEACCH model. In: Reynolds, CR.; Gutkin, TR., editors. *The Handbook of School Psychology*. Wiley; New York, NY: 1984. p. 629-643.
165. Rogers, SJ.; Hall, T.; Osaki, D.; Reaven, J.; Herbison, J. The Denver model: a comprehensive, integrated educational approach to young children with autism and their families. In: Handelman, JS.; Harris, SL., editors. *Preschool Education Programs for Children With Autism*. 2nd ed.. Pro-ed; Austin, TX: 2001. p. 95-134.
166. Koegel RL, Koegel LK, McNERNEY EK. Pivotal areas in intervention for autism. *J Clin Child Psychol* 2001;30(1):19–32. [PubMed: 11294074]
167. Smith, T.; Mazingo, D.; Mruzek, DW.; Zarcone, JR. Applied behavior analysis in the treatment of autism. In: Hollander, E.; Anagnostou, E., editors. *Clinical Manual for the Treatment of Autism*. American Psychiatric Publishing; Washington, DC: 2007. p. 153-177.
168. Braden, ML. Education. In: Weber, J., editor. *Children With Fragile X Syndrome: A Parent's Guide*. Woodbine House; Bethesda, MD: 2000. p. 243-305.
169. McConkie-Rosell A, Finucane BM, Cronister AC, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2005;14(4):249–270. [PubMed: 16047089]
170. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. *Genet Med* 2005;7(8):584–587. [PubMed: 16247297]
171. McConkie-Rosell A, Robinson H, Wake S, Staley LW, Heller K, Cronister A. Dissemination of genetic risk information to relatives in the fragile X syndrome: guidelines for genetic counselors. *Am J Med Genet* 1995;59(4):426–430. [PubMed: 8585560]
172. Gane, L.; Cronister, A. Genetic counseling. In: Hagerman, RJ.; Hagerman, PJ., editors. *The Fragile X Syndrome: Diagnosis, Treatment, and Research*. 3rd ed.. Johns Hopkins University Press; Baltimore, MD: 2002. p. 251-286.
173. Cederbaum S. Newborn screening: the spigot is open and threatens to become a flood. *J Pediatr* 2007;151(2):108–110. [PubMed: 17643755]
174. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. *Mov Disord* 2007;22(14):2018–2030. [PubMed: 17618523]
175. Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. *Am J Obstet Gynecol* 2005;192(6):1905–1912. [PubMed: 15970847]
176. Cronister A, DiMaio M, Mahoney MJ, Donnenfeld AE, Hallam S. Fragile X syndrome carrier screening in the prenatal genetic counseling setting. *Genet Med* 2005;7(4):246–250. [PubMed: 15834242]
177. Pessó R, Berkenstadt M, Cuckle H, et al. Screening for fragile X syndrome in women of reproductive age. *Prenat Diagn* 2000;20(8):611–614. [PubMed: 10951469]
178. Jacquemont S, Leehey MA, Hagerman RJ, Beckett LA, Hagerman PJ. Size bias of fragile X premutation alleles in late-onset movement disorders. *J Med Genet* 2006;43(10):804–809. [PubMed: 16723388]
179. Hall DA, Hagerman RJ, Hagerman PJ, Jacquemont S, Leehey MA. Prevalence of FMR1 repeat expansions in movement disorders: a systematic review. *Neuroepidemiology* 2006;26(3):151–155. [PubMed: 16493202]
180. Bailey DB Jr, Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. *Ment Retard Dev Disabil Res Rev* 2006;12(4):270–279. [PubMed: 17183569]

181. Bailey DB Jr, Skinner D, Sparkman KL. Discovering fragile X syndrome: family experiences and perceptions. *Pediatrics* 2003;111(2):407–416. [PubMed: 12563071]
182. Bailey DB Jr. Newborn screening for fragile X syndrome. *Ment Retard Dev Disabil Res Rev* 2004;10(1):3–10. [PubMed: 14994282]
183. Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. *Pediatrics* 2008;121(3) Available at: www.pediatrics.org/cgi/content/full/121/3/e693.
184. Strom CM, Huang D, Li Y, et al. Development of a novel, accurate, automated, rapid, high-throughput technique suitable for population-based carrier screening for fragile X syndrome. *Genet Med* 2007;9(4):199–207. [PubMed: 17438383]
185. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (*FMR1*) gene in newborn and high-risk populations. *J Mol Diagn* 2008;10(1):43–49. [PubMed: 18165273]

FIGURE 1.

Depiction of transcription and translation of the *FMR1* gene in normal individuals, individuals with the premutation, and individuals with the full mutation. The molecular pathogenesis is different in the premutation diseases, compared with the full mutation that leads to FXS. *FMR1* mRNA expression levels are increased with the premutation and decreased or absent with the full mutation. FMRP levels are absent or decreased with the full mutation and normal or close to normal with the premutation.

FIGURE 2.

Photograph and pedigree of a family in which the premutation and the full mutation have affected 4 generations. All family members included in the pedigree are in the photograph except one of the twin brothers with FXS. POI indicates primary ovarian insufficiency; nl, normal; pre, premutation; SAB, spontaneous abortion.

FIGURE 3.

Pathways in the cortex and hippocampus thought to be involved in the mGluR mechanism of mental retardation in FXS and expected effects of lithium, 2-methyl-6-(phenylethynyl)pyridine (MPEP)/mGluR blockers, and CX516/ampakines. In the normal state, mGluR activation by glutamate (glu) results in activation of dendritic translation through the phospholipase C (PLC) cascade. FMRP levels increase with translational activation, and FMRP then inhibits translation, acting as the negative feedback or “brake” on the translational mechanism. When FMRP is missing in FXS, mGluR-mediated translation lacks the negative feedback balance normally provided by FMRP and is activated excessively and constitutively, leading to excessive synthesis of specific synaptic proteins, internalization of AMPA receptors, and other

synaptic changes that result in excessive long-term depression and persistently weak and immature synapses. Treatment with 2-methyl-6-(phenylethynyl)pyridine or other mGluR5 negative modulators would block excessive mGluR-mediated translation directly. Lithium, which blocks inositol phosphate (IP) turnover, thus depleting phospholipase C substrate and blocking phospholipase C-mediated signal transduction, also inhibits glycogen synthase kinase 3 β (GSK3 β) activity, thus downregulating translation of FMRP target proteins, and would be expected to block in part excessively activated mGluR-mediated translation in FXS. In either case, the system would then move toward the normal level of translational activity, resulting in normalization of synaptic activity and maturation. Treatment with CX516 or other ampakines would be expected to increase AMPA activity directly, as well as redistributing AMPA receptors to the synaptic membrane through activation of BDNF. PKC indicates protein kinase C.